Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $183.87 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.27 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -49.09%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Alcidion Group Ltd (ASX: ALC)
Latest News

A man watches the share price movement closely.
Small Cap Shares

3 exciting small cap ASX shares to watch

Check out these highly rated small cap ASX shares...

Read more »

A businessman hugs his computer.
Broker Notes

4 fallen ASX shares that are still awesome businesses: expert

World events are taking stock prices down, but many businesses are still going as strong as ever. Here are some…

Read more »

Three children wearing athletic short and singlets stand side by side on a running track wearing medals around their necks and standing with their hands on their hips.
Small Cap Shares

3 growing small cap ASX shares going places

Here are three small caps to watch carefully...

Read more »

man looking through binoculars
Small Cap Shares

4 small cap ASX shares for your watchlist

Here is a group of small cap shares to watch...

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise such as the rising Xero share price over the past decade
Small Cap Shares

3 exciting small cap ASX shares to watch

Here are three small caps to watch closely...

Read more »

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Small Cap Shares

3 exciting small cap ASX shares rated as buys

Check out these highly rated small cap ASX shares...

Read more »

children being showered with gold confetti against a backdrop of gold 2022 balloons
Best Shares

Top ASX shares to buy in 2022

2021 has been an interesting year for investors. But what will the new year have in store for Aussie stocks?

Read more »

A woman sits at her computer in deep contemplation with her hand to her chin and seriously considering information she is receiving from the screen of her laptop regarding the Xero share price
Broker Notes

3 ASX shares now bargains after a nightmare November

This trio of stocks have had a foul few weeks. But are they now cheapies ready to rocket?

Read more »

ALC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Alcidion Group Ltd

Alcidion Group Ltd (ASX: ALC) is a Melbourne-based company focused on developing and licensing a range of software products for use in the healthcare sector. The company’s own brands include Miya, Patientrack and Smartpage and it also distributes selected products developed by its partner organisations.

Alcidion has offices and operations throughout Australia as well as in New Zealand and the United Kingdom. Its technology platforms are designed to improve the accuracy, efficiency and functionality of the often myriad of disconnected IT systems used in healthcare environments. As at October 2020, the company’s platforms are utilised by more than 65,000 users across over 300 hospitals in Australia, New Zealand and the UK.

According to Alcidion, the company is committed to continually innovating in its quest to support clinicians and improve the management and workflow of healthcare operations. Alcidion first listed on the ASX in mid-2011. The Alcidion share price has not been an overly strong performer and, despite reaching as high as 30 cents in late 2019, has spent much of the time since listing trading around or below 10 cents.

ALC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $0.14 $0.00 0.00% 1,274,017 $0.15 $0.15 $0.14
12 May 2022 $0.15 $0.00 0.00% 1,049,597 $0.15 $0.15 $0.15
11 May 2022 $0.15 $-0.01 -6.67% 2,249,212 $0.15 $0.16 $0.14
10 May 2022 $0.15 $-0.01 -6.45% 2,587,522 $0.15 $0.16 $0.14
09 May 2022 $0.16 $-0.01 -6.25% 1,148,775 $0.16 $0.16 $0.15
06 May 2022 $0.16 $-0.01 -6.06% 1,221,908 $0.17 $0.17 $0.16
05 May 2022 $0.17 $-0.01 -5.88% 1,248,101 $0.17 $0.17 $0.17
04 May 2022 $0.17 $0.00 0.00% 794,546 $0.18 $0.18 $0.17
03 May 2022 $0.17 $-0.01 -5.56% 662,157 $0.18 $0.18 $0.17
02 May 2022 $0.18 $0.01 5.71% 1,443,343 $0.18 $0.18 $0.17
29 Apr 2022 $0.18 $-0.01 -5.56% 2,343,857 $0.19 $0.19 $0.17
28 Apr 2022 $0.18 $-0.01 -5.41% 2,105,034 $0.19 $0.19 $0.18
27 Apr 2022 $0.19 $-0.01 -5.13% 2,034,030 $0.20 $0.20 $0.19
26 Apr 2022 $0.20 $-0.01 -5.00% 404,123 $0.20 $0.20 $0.20
22 Apr 2022 $0.20 $-0.01 -4.76% 1,322,682 $0.21 $0.21 $0.20
21 Apr 2022 $0.21 $0.01 4.88% 829,904 $0.21 $0.21 $0.20
20 Apr 2022 $0.21 $0.00 0.00% 1,032,030 $0.21 $0.21 $0.20

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
04 Jan 2022 Rebecca Wilson Issued 88 $36,141
Rights issue.
04 Jan 2022 Rebecca Wilson Issued 55 $36,141
Rights issue.
04 Jan 2022 Simon Chamberlain Issued 28 $7,024
Rights issue.
04 Jan 2022 Daniel Sharp Issued 28 $7,143
Rights issue.
23 Dec 2021 Simon Chamberlain Buy 194 $49,524
On-market trade.
23 Dec 2021 Victoria Weekes Buy 160 $41,587
On-market trade.
15 Dec 2021 Katrina (Kate) Doyle (Quirke) Issued 1 $250,000
Rights issue.
17 May 2021 Katrina (Kate) Doyle (Quirke) Sell 11 $3,903,632
On-market trade. As per announcement on 18/05/2021.
17 May 2021 Simon Chamberlain Buy 295 $100,300
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Rebecca Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
Ms Wilson has more than 20 years experience working within the healthcare, technology and life science sectors providing advice on stakeholder communications, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She advises boards and executive teams on investor relations and commercial strategies and has experience in transactions, including more than 60 IPOs, M&A transactions, and hundreds of capital raisings. Rebecca is an Executive Director of consulting firm WE Worldwide. She is a member and graduate of the Australian Institute of Company Directors (AICD).
Mr Simon Chamberlain Non-Executive Director Jul 2019
Mr has more than 20 years' experience in executive roles at companies including Experian, Medibank Private, Qantas and MedAdvisor and in his current role, leading strategy and marketing at the high growth residential services business, Detector Inspector. Simon led Qantas' entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simon's role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business.
Professor Malcolm Pradhan Executive Director Feb 2016
Professor Pradhan has over 25 years of experience in Medical Informatics. Malcolm has been a advocate for interoperability, and a sustainable health care system using smart data-driven IT systems that improve patient safety, reduce clinician workloads and support new models of care.
Ms Victoria Weekes Non-Executive Director Sep 2021
Ms Weekes has experience in the banking and finance sectors. Ms Weekes was the immediate past Acting Chair of the Sydney Local Health District Board and is an experienced Non-Executive Director with current appointments including FINSIA, NSW Treasury Audit and Risk, and St George Community Housing. Ms Weekes will Chair Alcidion's Risk Committee from 01/09/2021.
Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
Ms Quirke has more than 25 years of experience in the healthcare information technology sector. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, New Zealand and South East Asia. Kate's background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
Mr Daniel Sharp Non-Executive Director Sep 2021
Mr Sharp has more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organizations, and with a network of institutional and private wealth investors globally. He is an immediate past Executive Director of Canaccord Genuity and previously held executive senior corporate banking roles with Shaw and Partners and Lodge Partners.
Ms Melanie Jaye Leydin Company Secretary Mar 2019
-
Matthew Gepp Chief Financial Officer
-
Colin McKinnon Chief Operating Officer
-
Melanie Jaye Leydin Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Malcolm Pradhan 134,582,403 12.84%
Mr Raymond Blight 95,828,781 9.14%
J P Morgan Nominees Australia Pty Limited 55,835,785 5.33%
Isle of Wight Pty Limited 49,405,192 4.71%
Caledonia Nominees Pty Limited 35,976,377 3.43%
Mrs Katrina Doyle 27,793,199 2.65%
Rewmicman Pty Limited 26,026,606 2.48%
Rangiora-London Pty Limited 25,102,251 2.40%
Sandhurst Trustees Limited <JMFG CONSOL A/C> 24,453,360 2.33%
MNMD Pty Limited 18,668,086 1.78%
Citicorp Nominees Pty Limited 18,102,425 1.73%
HSBC Custody Nominees (Australia) Limited 16,552,966 1.58%
Mr Colin MacKinnon + Mrs Maree MacKinnon 9,676,550 0.92%
National Nominees Limited 9,618,072 0.92%
Sandhurst Trustees Limited <CYAN C3G FUND A/C> 7,819,114 0.75%
Rewmicman Pty Limited (i) 7,533,835 0.72%
BNP Paribas Noms Pty Ltd 6,233,372 0.59%
Emerald Shares Pty Limited 6,118,750 0.58%
Cs Third Nominees Pty Limited 5,680,121 0.54%
Mr Vivek Ramakrishnan + Miss Nisha Srinivasan 5,593,121 0.53%

Profile

since

Note